This application addresses broad Challenge Area (04) Clinical Research and specific Challenge Topic, 04-HL-110: Treatment of Pulmonary Hypertension and Right Heart Failure. PROJECT SUMMARY/ABSTRACT Pulmonary arterial hypertension (PAH) is an incurable, devastating disease with a high mortality rate. Characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, PAH ultimately leads to right heart failure and death. Current therapies improve hemodynamic measures but have significant drawbacks, including variable patient responses and continued deterioration in patient status. Because vasoconstriction of the pulmonary vessels characterizes the pathology of PAH, intravenous therapy with the potent vasodilator prostacyclin is often used in patients with PAH. However, this therapy is expensive and tethers the patient to a cumbersome delivery system comprising a continuous-infusion pump with an indwelling catheter. Developing a cell-based therapy that replenishes prostacyclin levels would overcome existing flaws in the treatment of patients with PAH and help stimulate development of this novel technology for other cardiovascular diseases. Our broad, long-term challenge is to develop a cell-based therapy using prostacyclin-secreting transfected cells to treat patients with PAH. Our immediate objectives for this proposal are to develop genetically engineered cells that stably overexpress prostacyclin (Specific Aim 1) and study their therapeutic potential in animal models (Specific Aim 2).
For Specific Aim 1, we plan to create and characterize rat and human transgenic cell lines overexpressing a recently developed novel fusion protein (COX-1-10aa-PGIS) that continuously produces and releases prostacyclin.
For Specific Aim 2, we will study the efficacy of the genetically engineered rat and human cell lines in treating PAH in animal models. We will use the well-established rat model of monocrotaline- induced PAH to examine the effects of COX-1-10aa-PGIS-overexpressing cells on survival and right ventricular systolic pressure and the right ventricular and left ventricular weight ratio, which are the most significant measures of PAH. In addition to efficacy, we will examine cell trafficking in rats by studying the tissue localization of fluorescently labeled prostacyclin-overexpressing transfected cells. Once we establish the efficacy of our cell lines in rats, we will study them in a large animal model that more closely resembles the human anatomy. In the pig model of shunt- induced PAH, we will similarly examine the in vivo distribution of fluorescently labeled transfected cells and monitor pulmonary pressures (via right heart catheterization) as an indicator of efficacy in treating PAH. We believe our work will provide the preclinical foundation to move this novel cell-based therapy for PAH forward into clinical trials.

Public Health Relevance

Pulmonary arterial hypertension is a rare but fatal disease, and current therapies are not curative and are associated with significant drawbacks. As part of a cell-based therapy approach, the objective of the current proposal is to develop and test in animal models genetically engineered rat and human cells that stably overexpress prostacyclin, a potent vasodilator that is reduced in patients with pulmonary arterial hypertension. These studies should provide sufficient preclinical data to allow this innovative cell therapy to move forward into clinical trials and help usher in a new era in the treatment of this devastating disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
NIH Challenge Grants and Partnerships Program (RC1)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CVRS-B (58))
Program Officer
Moore, Timothy M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Texas Heart Institute
United States
Zip Code